A r t i c l e Taleb, S., M. Romain, B. Ramkhelawon, C. Uyttenhove, G. Pasterkamp, O. Herbin, B. Esposito, N. Perez, H. Yasukawa, J. Van Snick, et al. 2009. Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis. J. Exp. Med. 206:2067–2077. doi:10.1084/jem.20090545 Tannahill, G.M., J. Elliott, A.C. Barry, L. Hibbert, N.A. Cacalano, and J.A. Johnston. 2005. SOCS2 can enhance interleukin-2 (IL-2) and IL-3 signaling by accelerating SOCS3 degradation. Mol. Cell. Biol. 25:9115– 9126. doi:10.1128/MCB.25.20.9115-9126.2005 Venge, J., M. Lampinen, L. Håkansson, S. Rak, and P. Venge. 1996. Identification of IL-5 and RANTES as the major eosinophil chemoat- tractants in the asthmatic lung. J. Allergy Clin. Immunol. 97:1110–1115. doi:10.1016/S0091-6749(96)70265-8 Walter, D.M., J.J. McIntire, G. Berry, A.N. McKenzie, D.D. Donaldson, R.H. DeKruyff, and D.T. Umetsu. 2001. Critical role for IL-13 in the de- velopment of allergen-induced airway hyperreactivity. J. Immunol. 167:4668–4675. Watford, W.T., C.C. Wang, C. Tsatsanis, L.A. Mielke, A.G. Eliopoulos, C. Daskalakis, N. Charles, S. Odom, J. Rivera, J. O’Shea, and P.N. Tsichlis. 2010. Ablation of tumor progression locus 2 promotes a type 2 Th cell response in Ovalbumin-immunized mice. J. Immunol. 184:105– 113. doi:10.4049/jimmunol.0803730 Yang, X.P., K. Ghoreschi, S.M. Steward-Tharp, J. Rodriguez-Canales, J. Zhu, J.R. Grainger, K. Hirahara, H.W. Sun, L. Wei, G. Vahedi, et al. 2011. Opposing regulation of the locus encoding IL-17 through direct, re- ciprocal actions of STAT3 and STAT5. Nat. Immunol. 12:247–254. doi:10.1038/ni.1995 Yoshimura, A., T. Naka, and M. Kubo. 2007. SOCS proteins, cytokine signalling and immune regulation. Nat. Rev. Immunol. 7:454–465. doi:10.1038/nri2093 Zhu, J., J. Cote-Sierra, L. Guo, and W.E. Paul. 2003. Stat5 activation plays a critical role in Th2 differentiation. Immunity. 19:739–748. doi:10.1016/S1074-7613(03)00292-9 JEM Vol. 208, No. 7 1531